Description
With over 130 products on the market worth $50bn, biologicals and biopharmaceuticals remain the fastest growing segment amongst novel pharmaceutical entities today. Mirroring this trend, the market for lyophilising these compounds, currently approaching 200 million units, is set to continue its year-on-year double digit growth.
